EVENTS

September 1st 2022

Catalent Job Day

Enregistrement : 16.30-17.00

Bienvenue & présentation du job day (Présentation de Catalent, Aptaskil - CEO BIOpark): 17.00-17.30

Stands : 17.30 – 19.00

Talent Acquisition – Equipe Recrutement (Europe)

• Ma carrière à Catalent, partage d’expérience – Pourquoi travailler à Catalent ?
• Equipe de Dusseldorf
• Equipe de Bruxelles
• Aptaskil – centre de formation

Workshops : 3 sessions par workshop (17.30 – 18.00/ 18.00 – 18.30/ 18.30 – 19.00)

• Workshop 1 : Nos activités de thérapie cellulaire
• Workshop 2 : Nos activités plasmides
• Workshop 3 : Nos activités de production biologiques

Visites des installations – campus Gosselies (17.30 – 18.00/ 18.00 – 18.30/ 18.30 – 19.00)

• Visite 1 : Zones de production (Thérapie Cellulaire) – 15 personnes max/visite
• Visite 2 : Laboratoires de développement (activités plasmides) – 15 personnes max/visite
• Visite 3 : Infrastructures dédiées à nos futures activités commerciales – 20 personnes max/visite (avec navette)

01.09.2022 / 4:30 > 8:00 PM Point Centre - Av. Georges Lemaître 19B, 6041 Gosselies

August 15th - 16th 2019

Coolerr Bags Information

Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patients with Acute-on-Chronic Liver Failure. Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patients with Acute-on-Chronic Liver Failure. Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patients with Acute-on-Chronic Liver Failure.

15.08.2019 - 16.07.2021 / 12:00 > 4:00 PM 58 Greta Street

August 14th - 29th 2019

PROMETHERA BIOSCIENCES ANNOUNCES LATE-BREAKING DATA PRESENTATION

Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patients with Acute-on-Chronic Liver Failure. Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patients with Acute-on-Chronic Liver Failure. Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patients with Acute-on-Chronic Liver Failure.

14.08.2019 - 29.07.2021 / 7:00 > 12:00 PM ULiège - UMONS

August 1st - 13th 2019

UMONS, ULB, ULG INAUGURATE THE MASS SPECTROMETRY PLATFORM MS-QUANTA

Masthercell announces today that it has signed a lease agreement for a 5.700 m2 facility located in Gosselies. The new facility will become a state-of-the-art manufacturing and production site designed for late-stage and commercially-approved cell. Masthercell announces today that it has signed a lease agreement for a 5.700 m2 facility located in Gosselies. The new facility will become a state-of-the-art manufacturing and production site designed for late-stage and commercially-approved cell. Masthercell announces today that it has signed a lease agreement for a 5.700 m2 facility located in Gosselies. The new facility will become a state-of-the-art manufacturing and production site designed for late-stage and commercially-approved cell.

01.08.2019 - 13.08.2020 / 12:00 > 4:00 PM ULiège - UMONS